BioSpace News Archive

Your Feedback Matters! Career Path Direction

As a valued member of our BioSpace community, we are eager to hear more from you and other readers in 2019. We want to know your career path direction you took or plan to take.

September 23, 2019
·
1 min read
·
BioSpace Staff
Drug Development

Neurana Pharmaceuticals Announces Positive Topline Results from Phase 2 STAR Study of Tolperisone in Acute Muscle Spasms of the Back

Neurana Pharmaceuticals, a biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, today announced positive topline results from the “STAR Study”, a Phase 2 dose-ranging study of tolperisone in acute muscle spasms of the back

September 23, 2019
·
3 min read
Deals

Global medtech revenues reach all-time high, yet innovation investments lag

The global medical technology industry continues to grow, but its long-term growth outlook is at risk due to underinvestment in R&D and lack of collaboration between industry providers, payers and patients.

September 23, 2019
·
5 min read
Drug Development

Ipsen announces positive results from Phase IIIb/IV ENGAGE study of the combination of Dysport® (abobotulinumtoxinA) with Guided Self-rehabilitation Contracts in adult patients with upper and lower limb spastic hemiparesis1,2,3,4

Results presented at the International Congress of Parkinson’s Disease and Movement Disorders (MDS) in Nice, France, 22-26 September 2019

September 23, 2019
·
17 min read
4D pharma plc: Publication of Data on Neurodegenerative Disease Programmes

4D pharma announces the publication of data highlighting the neuroprotective properties of MRx0005 and MRx0029

September 23, 2019
·
2 min read
Drug Development

GenSight Biologics Reports Sustained Efficacy and Safety at 96 Weeks in RESCUE Phase III Clinical Trial of GS010 for the Treatment of Leber Hereditary Optic Neuropathy (LHON)

GenSight Biologics, a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported the first set of results from Week 96 of the RESCUE Phase III clinical trial.

September 23, 2019
·
12 min read
New Data at ESMO 2019 for Merck KGaA, Darmstadt, Germany, Highlight Focused Clinical Development and Commitment to Patient Care

Merck KGaA, Darmstadt, Germany announced that new data representing several key therapeutic agents from its diverse oncology pipeline will be presented at the 2019 European Society for Medical Oncology Congress, September 27–October 1, in Barcelona, Spain.

September 23, 2019
·
25 min read
Deals

Vedanta Biosciences Announces $16.6 Million Series C-2 Financing

Vedanta Biosciences, announced a $16.6 million Series C-2 financing round, bringing the total capital raised in its Series C and C-2 round to $62.1 million.

September 23, 2019
·
4 min read
Policy

3M and Clean Air Asia Act on Climate Change with New Air Pollution Initiative

Coinciding with its participation in Climate Week and the United Nations Climate Action Summit, 3M is acting on climate change through a new partnership with Clean Air Asia.

September 23, 2019
·
4 min read
Biotech Bay

BioVentrix Announces Study Design for REVIVE-HF: Randomized Controlled Trial (RCT) in Europe

To demonstrate that treatment with the Revivent TC™ System is more effective than Guideline Directed Medical Therapy (GDMT) for the treatment of ischemic heart failure

September 23, 2019
·
2 min read